Compare · AXNX vs MDLN
AXNX vs MDLN
Side-by-side comparison of Axonex AI Group Limited (AXNX) and Medline Inc. (MDLN): market cap, price performance, sector, and recent activity on the wire.
Summary
- AXNX operates in Consumer Discretionary, while MDLN operates in Health Care - the two are in different parts of the market.
- MDLN is the larger of the two at $49.56B, about 8664.3x AXNX ($5.7M).
- MDLN has hit the wire 14 times in the past 4 weeks while AXNX has been quiet.
- MDLN has more recent analyst coverage (25 ratings vs 21 for AXNX).
- Company
- Axonex AI Group Limited
- Medline Inc.
- Price
- -
- -
- Market cap
- $5.7M
- $49.56B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Business Services
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2018
- 2025
- News (4w)
- 0
- 14
- Recent ratings
- 21
- 25
Axonex AI Group Limited
Axonex AI Group Limited (formerly Mint Incorporation Limited) (NASDAQ: AXNX) is a Hong Kong-based company strategically focused on artificial intelligence (AI) and robotics, and an established business interior design and fit-out works provider. Through its subsidiary, Axonex AI Limited, and its majority owned subsidiary, Rice Robotics AGI Holding Limited, the Group delivers robot models and robotics solutions, including the FLOKI Minibot M1 and micro-insurance solutions purpose-built for commercial robots. The Group also maintains its established interior design and fit-out works business. Anchored by its ongoing transformation, Axonex AI is focused on AI and robotics as its main growth driving engine.
Latest AXNX
- Axonex AI Group Limited Announces 2-for-5 Reverse Stock Split
- Axonex AI Group Joins FLAIR’s Embodied AI International Applications Hub and Launches Education Humanoid TOMO
- Axonex AI Group Limited (NASDAQ: AXNX) Solidifies Transformation into an AI and Robotics-Focused Company
- CAIRDAC Announces the Appointment of Raymond W. Cohen as Chairman of its Board of Directors
- RxSight, Inc. Appoints Raymond W. Cohen to Its Board of Directors
- SEC Form 15-12G filed by Axonics Inc.
- SEC Form EFFECT filed by Axonics Inc.
- SEC Form 25-NSE filed by Axonics Inc.
- Director Kiernan Jane E returned $1,410,131 worth of shares to the company (19,861 units at $71.00), closing all direct ownership in the company (SEC Form 4)
- EVP, Chief Mktg/Strtgy Officer Woock John returned $5,495,613 worth of shares to the company (77,403 units at $71.00), closing all direct ownership in the company (SEC Form 4)
Latest MDLN
- Medline Inc. announces pricing of secondary offering of Class A common stock
- Chief Legal Officer Liberman Alexander M. was granted 798,680 units of Class B Common Stock, increasing direct ownership by 352% to 1,025,603 units (SEC Form 4)
- Chief Product Officer Laabs Amanda H. was granted 520,127 units of Class B Common Stock, increasing direct ownership by 207% to 771,197 units (SEC Form 4)
- Chief Commercial Officer Golwas Douglas P was granted 895,512 units of Class B Common Stock, increasing direct ownership by 164% to 967,560 units (SEC Form 4)
- Chief Executive Officer Boyle James M was granted 2,516,260 units of Class B Common Stock, increasing direct ownership by 7,591% to 1,869,921 units (SEC Form 4)
- Medline Inc. announces launch of secondary offering of Class A common stock
- SEC Form S-1 filed by Medline Inc.
- SEC Form SCHEDULE 13G filed by Medline Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by Medline Inc.
- SEC Form 10-Q filed by Medline Inc.